Get the Stockscreener App
23.31
1.08%
0.25
Tourmaline Bio Inc stock is traded at $23.31, with a volume of 126.01K.
It is up +1.08% in the last 24 hours and up +23.59% over the past month.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
See More
Previous Close:
$23.06
Open:
$23.3
24h Volume:
126.01K
Relative Volume:
0.52
Market Cap:
$598.89M
Revenue:
-
Net Income/Loss:
$11.77M
P/E Ratio:
40.29
EPS:
0.5785
Net Cash Flow:
$-19.23M
1W Performance:
+3.28%
1M Performance:
+23.59%
6M Performance:
+90.91%
1Y Performance:
+63.69%
1-Day Range:
$22.95
$24.00
1-Week Range:
$21.30
$24.00
52-Week Range:
$11.56
$29.79
Tourmaline Bio Inc Stock (TRML) Company Profile
Name
Tourmaline Bio Inc
Sector
Industry
Phone
646-481-9832
Address
27 WEST 24TH STREET, NEW YORK
Compare TRML with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
23.31 | 569.60M | 0 | 11.77M | -19.23M | 0.5785 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Nov-11-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-15-23 | Initiated | Jefferies | Buy |
| Dec-04-23 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Oct-31-23 | Initiated | Guggenheim | Buy |
| Oct-25-23 | Initiated | Piper Sandler | Overweight |
| Oct-20-22 | Initiated | H.C. Wainwright | Buy |
| Jul-05-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
View All
Tourmaline Bio Inc Stock (TRML) Latest News
Is Tourmaline Bio Inc. trending in predictive chart models2025 Top Decliners & Safe Swing Trade Setups - Newser
Multi asset correlation models including Tourmaline Bio Inc.Weekly Trade Report & Weekly Sector Rotation Insights - Newser
How to use a screener to detect Tourmaline Bio Inc. breakoutsEarnings Recap Summary & Weekly Top Gainers Trade List - Newser
Real time breakdown of Tourmaline Bio Inc. stock performanceJuly 2025 Trends & Momentum Based Trading Ideas - Newser
Multi factor analysis applied to Tourmaline Bio Inc.Weekly Investment Recap & Fast Moving Market Watchlists - Newser
Is Tourmaline Bio Inc. stock entering bullish territory2025 Top Gainers & Fast Entry Momentum Alerts - Newser
Analyzing Zevra Therapeutics (NASDAQ:ZVRA) and Tourmaline Bio (NASDAQ:TRML) - Defense World
Will Tourmaline Bio Inc. continue its uptrendBond Market & Real-Time Market Sentiment Alerts - Newser
Is Tourmaline Bio Inc. stock ready for a breakoutExit Point & Intraday High Probability Setup Alerts - Newser
Exit strategy if you’re trapped in Tourmaline Bio Inc.Trend Reversal & Fast Exit/Entry Strategy Plans - Newser
Will a bounce in Tourmaline Bio Inc. offer an exit2025 Market Outlook & Stepwise Entry and Exit Trade Signals - Newser
Detecting support and resistance levels for Tourmaline Bio Inc.July 2025 Pullbacks & High Conviction Buy Zone Alerts - Newser
How high can Tourmaline Bio Inc. stock goRate Hike & Daily Stock Trend Reports - Newser
Tourmaline Bio Inc. Company Revenue and Profit Trends: A Deep DivePortfolio Gains Report & Long Hold Capital Preservation Plans - Newser
Detecting support and resistance levels for Tourmaline Bio IncJuly 2025 Gainers & Technical Entry and Exit Tips - Newser
Analysts Set Expectations for Tourmaline Bio FY2025 Earnings - Defense World
Lifesci Capital Expects Higher Earnings for Tourmaline Bio - Defense World
Tourmaline Bio Q3 EPS Forecast Raised by Leerink Partnrs - Defense World
What is Wedbush’s Forecast for Tourmaline Bio Q3 Earnings? - Defense World
Analyzing Tourmaline Bio Inc. with risk reward ratio chartsCPI Data & Weekly Breakout Stock Alerts - Newser
Comparing Tourmaline Bio Inc. in custom built stock radarsWeekly Trade Report & Precise Swing Trade Entry Alerts - Newser
Tourmaline Bio Inc. Recovery Hinges on Volume BreakoutMarket Activity Report & Safe Entry Point Alerts - news-j.co.kr
Is Tourmaline Bio Inc. a candidate for recovery play2025 Bull vs Bear & Smart Money Movement Alerts - Newser
How to track smart money flows in Tourmaline Bio Inc.Quarterly Trade Review & Long-Term Growth Portfolio Plans - Newser
Tourmaline Bio’s (TRML) Buy Rating Reiterated at Guggenheim - Defense World
What to do if you’re stuck in Tourmaline Bio Inc.Dollar Strength & Real-Time Market Trend Scan - Newser
Can momentum traders help lift Tourmaline Bio Inc.July 2025 Action & Weekly Top Stock Performers List - Newser
Analyzing Tourmaline Bio Inc. with multi timeframe charts2025 Growth vs Value & AI Enhanced Trading Signals - Newser
Short Term Trend Reversal in Tourmaline Bio Inc. Possible2025 Analyst Calls & Momentum Based Trading Ideas - beatles.ru
Is Tourmaline Bio Inc. Stock Overbought or Oversold RSI Indicator AnalysisEarnings Performance Report & Growth-Oriented Investment Plans - Newser
Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know - MSN
Building trade automation scripts for Tourmaline Bio Inc.2025 Year in Review & Fast Moving Stock Trade Plans - Newser
Tourmaline Bio’s Promising Developments and Strategic Potential: Analyst Recommends ‘Buy’ Rating - TipRanks
Tourmaline Bio’s Strategic Advancements and Promising Clinical Trial Results Reinforce Buy Rating - TipRanks
Unlocking Long-Term Value in Biotechnology: The Case for Tourmaline Bio's Disruptive Innovation - AInvest
Tourmaline Bio (NASDAQ:TRML) Given “Buy” Rating at Chardan Capital - Defense World
Is There Enough Volume to Lift Tourmaline Bio Inc.Market Performance Summary & Weekly High Return Forecasts - newsyoung.net
Tourmaline Bio Inc. Reversal Rally May Surprise BearsPrice Action & AI Enhanced Execution Alerts - sundaytimes.kr
Tourmaline Bio Inc Stock (TRML) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):